The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
877
GASTROPARESIS RISK IN PATIENTS WITH TYPE 2 DIABETES PRESCRIBED GLP-1 RECEPTOR AGONISTS
Date
May 20, 2024
Explore related products in the following collection:
BACKGROUND: As outlined by the Kyoto guidelines, targeted DNA-based NGS of pancreatic cyst fluid (PCF) is an important adjunct to the evaluation of pancreatic cyst patients…
BACKGROUND: Recent studies suggest links between _Clostridioides difficile_ infection (CDI) and liver disorders, with non-alcoholic fatty liver disease (NAFLD) increasing CDI risk and CDI exacerbating the progression and prognosis of liver cirrhosis. Moreover, gut dysbiosis, often leading to _C…
Oral small molecules (OSM) have demonstrated effectiveness in treating IBD. Certain studies have associated certain OSM with an increased cancer risk. We aimed to assess the cancer risk in IBD patients treated with OSM…